JCB, Volume 20, Number 1, 2014 Article Vol.20 No. 1 (2014) Russia-Focused Venture Capital Supports In-Bound Technology Transfer and Company Building: An Analysis of Investment Trends and Outcomes John M. Garvey This paper analyzes the approaches taken by the Russian government to promote innovation in the biotechnology sector within the country. Russia is economically strong, currently with a t Article Vol.20 No. 1 (2014) Funding biotech start-ups in a post-VC world William Bains Investment in start-up biotech. companies outside the USA has essentially disappeared. VC investment in biotechnology and healthcare as a whole has nearly returned to pre-2008 levels, but Article Vol.20 No. 1 (2014) Biotechnology Venture Investing and Neurodegenerative Medicine: Promise of New Approaches to Cure an Ailing Model Dushon DeVere Riley Neurodegenerative diseases are one of the leading public health challenges of the next 50 years. Pharmaceutical therapies have traditionally targeted the later stages of neurodegenerative Case Study Vol.20 No. 1 (2014) A biological battlefield: The potential applications of using remote sensing technology and biomarker organisms for identifying, tracking, and differentiating persons of interest within an area of operations Jason Rivera Since World War II, the majority of American wartime engagements have been characterized by a series of low-intensity, asymmetric conflicts. These conflicts have increased the importance Case Study Vol.20 No. 1 (2014) How a large biotechnology company teamed with a translation service provider to define best practices Jeremy Coombs According to the World Intellectual Property Organization, nearly 100,000 pharmaceutical and biotechnology patent applications are filed each year around the world, and the trend is incre From the Boardroom Vol.20 No. 1 (2014) A Social Media Manifesto Peter J. Pitts The role of marketing communications is to advance the bottom line Legal and Regulatory Updates Vol.20 No. 1 (2014) Raw materials intended to be used for Gene, Cell and Tissue therapies: legal and regulatory considerations Sophie Bisson This paper offers some insights on the European regulatory situation with respect to raw materials used in production of gene, cell and tissue therapy products, including advanced therapy me Legal and Regulatory Updates Vol.20 No. 1 (2014) EU Legal & Regulatory Update Ewan Grist
